Is AURA or OTLK more profitable?

Oncobiologics' return on equity of 0.00% beat Aura Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Aura Biosciences N/A -73.18% -62.00% Oncobiologics N/A N/A -254.82%

Is STTK or OTLK more profitable?

Oncobiologics' return on equity of 0.00% beat Shattuck Labs' return on equity. Company Net Margins Return on Equity Return on Assets Shattuck Labs N/A -43.57% -40.90% Oncobiologics N/A N/A -254.82%

Does the media favor STTK or OTLK?

In the previous week, Shattuck Labs had 7 more articles in the media than Oncobiologics. MarketBeat recorded 8 mentions for Shattuck Labs and 1 mentions for Oncobiologics. Shattuck Labs' average media sentiment score of 0.35 beat Oncobiologics' score of 0.00 indicating that Shattuck Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Shattuck Labs 0 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oncobiologics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, ALT or OTLK?

Oncobiologics has higher revenue and earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Altimmune $40K 13,275.99 -$88.09M -$0.78 N/A Oncobiologics $1.35M 106.94 -$62.42M -$0.77 N/A

Is ALT or OTLK more profitable?

Oncobiologics' return on equity of 0.00% beat Altimmune's return on equity. Company Net Margins Return on Equity Return on Assets Altimmune N/A -31.41% -26.96% Oncobiologics N/A N/A -254.82%

Does the media refer more to ALT or OTLK?

In the previous week, Altimmune had 3 more articles in the media than Oncobiologics. MarketBeat recorded 4 mentions for Altimmune and 1 mentions for Oncobiologics. Altimmune's average media sentiment score of 0.02 beat Oncobiologics' score of 0.00 indicating that Altimmune is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Altimmune 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Oncobiologics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is VALN or OTLK more profitable?

Oncobiologics has a net margin of 0.00% compared to Valneva's net margin of -110.33%. Oncobiologics' return on equity of 0.00% beat Valneva's return on equity. Company Net Margins Return on Equity Return on Assets Valneva -110.33% -153.20% -39.50% Oncobiologics N/A N/A -254.82%

Does the media favor VALN or OTLK?

In the previous week, Valneva and Valneva both had 1 articles in the media. Valneva's average media sentiment score of 0.00 equaled Oncobiologics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valneva 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oncobiologics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CTMX or OTLK?

In the previous week, CytomX Therapeutics had 2 more articles in the media than Oncobiologics. MarketBeat recorded 3 mentions for CytomX Therapeutics and 1 mentions for Oncobiologics. CytomX Therapeutics' average media sentiment score of 0.10 beat Oncobiologics' score of 0.00 indicating that CytomX Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Oncobiologics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Oncobiologics (OTLK) Competitors

$0.59 +0.02 (+3.13%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$0.60 +0.00 (+0.51%)

As of 10/2/2026 07:58 PM Eastern

Compare

OTLK vs. AURA, STTK, ALT, VALN, and CTMX

Should you buy Oncobiologics stock or one of its competitors? Oncobiologics's main competitors and comparable companies include Aura Biosciences (AURA), Shattuck Labs (STTK), Altimmune (ALT), Valneva (VALN), and CytomX Therapeutics (CTMX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Oncobiologics compare to Aura Biosciences?

Aura Biosciences (NASDAQ:AURA) and Oncobiologics (NASDAQ:OTLK) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

96.8% of Aura Biosciences shares are owned by institutional investors. Comparatively, 11.2% of Oncobiologics shares are owned by institutional investors. 1.9% of Aura Biosciences shares are owned by company insiders. Comparatively, 1.8% of Oncobiologics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Oncobiologics had 1 more articles in the media than Aura Biosciences. MarketBeat recorded 1 mentions for Oncobiologics and 0 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 0.00 equaled Oncobiologics'average media sentiment score.

Company	Overall Sentiment
Aura Biosciences	Neutral
Oncobiologics	Neutral

Aura Biosciences currently has a consensus price target of $17.50, suggesting a potential upside of 187.36%. Oncobiologics has a consensus price target of $5.20, suggesting a potential upside of 776.90%. Given Oncobiologics' higher probable upside, analysts clearly believe Oncobiologics is more favorable than Aura Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Oncobiologics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Aura Biosciences has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market. Comparatively, Oncobiologics has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market.

Oncobiologics has higher revenue and earnings than Aura Biosciences. Aura Biosciences is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.75	N/A
Oncobiologics	$1.35M	106.94	-$62.42M	-$0.77	N/A

Oncobiologics' return on equity of 0.00% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-73.18%	-62.00%
Oncobiologics	N/A	N/A	-254.82%

Summary

Oncobiologics beats Aura Biosciences on 8 of the 12 factors compared between the two stocks.

How does Oncobiologics compare to Shattuck Labs?

Shattuck Labs (NASDAQ:STTK) and Oncobiologics (NASDAQ:OTLK) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

Shattuck Labs has higher earnings, but lower revenue than Oncobiologics. Shattuck Labs is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	675.42	-$48.81M	-$0.51	N/A
Oncobiologics	$1.35M	106.94	-$62.42M	-$0.77	N/A

Oncobiologics' return on equity of 0.00% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-43.57%	-40.90%
Oncobiologics	N/A	N/A	-254.82%

58.7% of Shattuck Labs shares are owned by institutional investors. Comparatively, 11.2% of Oncobiologics shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by company insiders. Comparatively, 1.8% of Oncobiologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Shattuck Labs currently has a consensus price target of $13.33, indicating a potential upside of 98.12%. Oncobiologics has a consensus price target of $5.20, indicating a potential upside of 776.90%. Given Oncobiologics' higher possible upside, analysts clearly believe Oncobiologics is more favorable than Shattuck Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
Oncobiologics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Shattuck Labs had 7 more articles in the media than Oncobiologics. MarketBeat recorded 8 mentions for Shattuck Labs and 1 mentions for Oncobiologics. Shattuck Labs' average media sentiment score of 0.35 beat Oncobiologics' score of 0.00 indicating that Shattuck Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shattuck Labs	0 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oncobiologics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Shattuck Labs has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market. Comparatively, Oncobiologics has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market.

Summary

Shattuck Labs beats Oncobiologics on 12 of the 16 factors compared between the two stocks.

How does Oncobiologics compare to Altimmune?

Altimmune (NASDAQ:ALT) and Oncobiologics (NASDAQ:OTLK) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

Oncobiologics has higher revenue and earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altimmune	$40K	13,275.99	-$88.09M	-$0.78	N/A
Oncobiologics	$1.35M	106.94	-$62.42M	-$0.77	N/A

In the previous week, Altimmune had 3 more articles in the media than Oncobiologics. MarketBeat recorded 4 mentions for Altimmune and 1 mentions for Oncobiologics. Altimmune's average media sentiment score of 0.02 beat Oncobiologics' score of 0.00 indicating that Altimmune is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Altimmune	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Oncobiologics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Altimmune has a beta of 0.06, suggesting that its stock price is 94% less volatile than the broader market. Comparatively, Oncobiologics has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market.

78.1% of Altimmune shares are held by institutional investors. Comparatively, 11.2% of Oncobiologics shares are held by institutional investors. 1.6% of Altimmune shares are held by company insiders. Comparatively, 1.8% of Oncobiologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Oncobiologics' return on equity of 0.00% beat Altimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Altimmune	N/A	-31.41%	-26.96%
Oncobiologics	N/A	N/A	-254.82%

Altimmune presently has a consensus price target of $14.33, suggesting a potential upside of 425.03%. Oncobiologics has a consensus price target of $5.20, suggesting a potential upside of 776.90%. Given Oncobiologics' higher possible upside, analysts plainly believe Oncobiologics is more favorable than Altimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Altimmune	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Oncobiologics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Oncobiologics beats Altimmune on 8 of the 15 factors compared between the two stocks.

How does Oncobiologics compare to Valneva?

Valneva (NASDAQ:VALN) and Oncobiologics (NASDAQ:OTLK) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

Oncobiologics has lower revenue, but higher earnings than Valneva. Valneva is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valneva	$197.56M	2.76	-$130.33M	-$2.11	N/A
Oncobiologics	$1.35M	106.94	-$62.42M	-$0.77	N/A

In the previous week, Valneva and Valneva both had 1 articles in the media. Valneva's average media sentiment score of 0.00 equaled Oncobiologics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valneva	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oncobiologics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Valneva has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market. Comparatively, Oncobiologics has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market.

Valneva presently has a consensus target price of $9.30, suggesting a potential upside of 62.02%. Oncobiologics has a consensus target price of $5.20, suggesting a potential upside of 776.90%. Given Oncobiologics' stronger consensus rating and higher probable upside, analysts plainly believe Oncobiologics is more favorable than Valneva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valneva	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Oncobiologics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

11.4% of Valneva shares are owned by institutional investors. Comparatively, 11.2% of Oncobiologics shares are owned by institutional investors. 14.9% of Valneva shares are owned by insiders. Comparatively, 1.8% of Oncobiologics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Oncobiologics has a net margin of 0.00% compared to Valneva's net margin of -110.33%. Oncobiologics' return on equity of 0.00% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valneva	-110.33%	-153.20%	-39.50%
Oncobiologics	N/A	N/A	-254.82%

Summary

Oncobiologics beats Valneva on 9 of the 14 factors compared between the two stocks.

How does Oncobiologics compare to CytomX Therapeutics?

CytomX Therapeutics (NASDAQ:CTMX) and Oncobiologics (NASDAQ:OTLK) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.

Oncobiologics has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -435.21%. Oncobiologics' return on equity of 0.00% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-435.21%	-38.46%	-30.33%
Oncobiologics	N/A	N/A	-254.82%

CytomX Therapeutics has higher revenue and earnings than Oncobiologics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$18.30M	30.48	-$17.37M	-$0.50	N/A
Oncobiologics	$1.35M	106.94	-$62.42M	-$0.77	N/A

67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 11.2% of Oncobiologics shares are owned by institutional investors. 3.8% of CytomX Therapeutics shares are owned by company insiders. Comparatively, 1.8% of Oncobiologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

CytomX Therapeutics currently has a consensus price target of $11.90, suggesting a potential upside of 364.84%. Oncobiologics has a consensus price target of $5.20, suggesting a potential upside of 776.90%. Given Oncobiologics' higher probable upside, analysts clearly believe Oncobiologics is more favorable than CytomX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Oncobiologics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, CytomX Therapeutics had 2 more articles in the media than Oncobiologics. MarketBeat recorded 3 mentions for CytomX Therapeutics and 1 mentions for Oncobiologics. CytomX Therapeutics' average media sentiment score of 0.10 beat Oncobiologics' score of 0.00 indicating that CytomX Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oncobiologics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CytomX Therapeutics has a beta of 2.21, meaning that its stock price is 121% more volatile than the broader market. Comparatively, Oncobiologics has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market.

Summary

CytomX Therapeutics beats Oncobiologics on 12 of the 17 factors compared between the two stocks.

Get Oncobiologics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OTLK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OTLK vs. The Competition

Export

Metric	Oncobiologics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$139.98M	$3.87B	$7.14B	$13.17B
Dividend Yield	N/A	3.64%	2.53%	16.78%
P/E Ratio	-0.77	13.06	275.68	26.04
Price / Sales	-124.08	1,373.91	658.18	100.99
Price / Cash	N/A	122.60	77.60	51.75
Price / Book	-0.99	16.63	10.93	6.31
Net Income	-$62.42M	-$22.71M	$3.51B	$362.16M
7 Day Performance	-7.34%	-2.99%	-2.01%	-1.66%
1 Month Performance	-8.63%	-10.60%	-6.15%	-4.50%
1 Year Performance	-44.06%	19.44%	7.44%	2.06%

Oncobiologics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OTLK Oncobiologics	2.8274 of 5 stars	$0.59 +3.1%	$5.20 +776.9%	-44.6%	$139.98M	-$1.16M	N/A	17	News Coverage Gap Up
AURA Aura Biosciences	1.3099 of 5 stars	$6.01 -2.4%	$17.50 +191.4%	+1.2%	$622.78M	N/A	N/A	113
STTK Shattuck Labs	2.4583 of 5 stars	$6.09 -3.6%	$12.78 +110.0%	+184.0%	$611.19M	$1M	N/A	40	News Coverage Analyst Forecast Gap Up
ALT Altimmune	1.9077 of 5 stars	$3.07 +0.8%	$14.33 +367.6%	-30.5%	$596.20M	$40K	N/A	57
VALN Valneva	2.0753 of 5 stars	$6.21 -0.2%	$9.30 +49.9%	-50.0%	$588.79M	$197.56M	N/A	674

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OTLK) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oncobiologics (OTLK) Competitors

OTLK vs. AURA, STTK, ALT, VALN, and CTMX

How does Oncobiologics compare to Aura Biosciences?

Summary

How does Oncobiologics compare to Shattuck Labs?

Summary

How does Oncobiologics compare to Altimmune?

Summary

How does Oncobiologics compare to Valneva?

Summary

How does Oncobiologics compare to CytomX Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OTLK vs. The Competition

Oncobiologics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oncobiologics (OTLK) Competitors

OTLK vs. AURA, STTK, ALT, VALN, and CTMX

How does Oncobiologics compare to Aura Biosciences?

Do institutionals and insiders have more ownership in AURA or OTLK?

Does the media refer more to AURA or OTLK?

Do analysts recommend AURA or OTLK?

Which has more volatility & risk, AURA or OTLK?

Which has better valuation & earnings, AURA or OTLK?

Is AURA or OTLK more profitable?

Summary

How does Oncobiologics compare to Shattuck Labs?

Which has higher valuation & earnings, STTK or OTLK?

Is STTK or OTLK more profitable?

Do insiders & institutionals have more ownership in STTK or OTLK?

Do analysts prefer STTK or OTLK?

Does the media favor STTK or OTLK?

Which has more risk and volatility, STTK or OTLK?

Summary

How does Oncobiologics compare to Altimmune?

Which has stronger valuation & earnings, ALT or OTLK?

Does the media refer more to ALT or OTLK?

Which has more risk & volatility, ALT or OTLK?

Do institutionals & insiders hold more shares of ALT or OTLK?

Is ALT or OTLK more profitable?

Do analysts rate ALT or OTLK?

Summary

How does Oncobiologics compare to Valneva?

Which has stronger earnings & valuation, VALN or OTLK?

Does the media favor VALN or OTLK?

Which has more volatility and risk, VALN or OTLK?

Do analysts recommend VALN or OTLK?

Do insiders & institutionals hold more shares of VALN or OTLK?

Is VALN or OTLK more profitable?

Summary

How does Oncobiologics compare to CytomX Therapeutics?

Is CTMX or OTLK more profitable?

Which has higher valuation & earnings, CTMX or OTLK?

Do insiders and institutionals hold more shares of CTMX or OTLK?

Do analysts prefer CTMX or OTLK?

Does the media favor CTMX or OTLK?

Which has more volatility & risk, CTMX or OTLK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OTLK vs. The Competition

Oncobiologics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools